FDA Clearance Tracker · P120005-S090
DEXCOM G5 Mobile Continuous Glucose Monitoring System
Last checked: Nov 20, 2026Latest source record: Jan 12, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Jan 12, 2023
Approved
Time to decision
90 days
Received Oct 14, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P120005-S090
- Device name
- DEXCOM G5 Mobile Continuous Glucose Monitoring System
- Applicant
- Dexcom, Inc.
- Applicant location
- San Diego, CA
- Received
- Oct 14, 2022
- Decided
- Jan 12, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P120005
Device type
- Device type
- Sensor, glucose, invasive (MDS)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval to modify the prior inclusion criterion to the following: Clinical diagnosis of Type 1 or Type 2 diabetes with at least one (1) week of insulin initiation at time of study entry.
Source documents
Other decisions for Dexcom, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262472 · Decided Aug 11, 2026 · 25 days after receipt
Device type: Integrated Continuous Glucose Monitor For Non-Intensive Glucose Management, Over-The-Counter (SBH) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.